BridgeBio Pharma Inc (NASDAQ:BBIO) has a beta value of 1.13 and has seen 1.19 million shares traded in the recent trading session. The company, currently valued at $8.47B, closed the recent trade at $44.58 per share which meant it gained $0.13 on the day or 0.30% during that session. The BBIO stock price is -0.38% off its 52-week high price of $44.75 and 51.28% above the 52-week low of $21.72. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.11 million shares traded. The 3-month trading volume is 2.95 million shares.
The consensus among analysts is that BridgeBio Pharma Inc (BBIO) is Buy stock at the moment, with a recommendation rating of 1.35. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 9 have rated it as a Hold, with 9 advising it as a Buy. 0 have rated the stock as Underweight.
BridgeBio Pharma Inc (NASDAQ:BBIO) trade information
Sporting 0.30% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the BBIO stock price touched $44.58 or saw a rise of 1.33%. Year-to-date, BridgeBio Pharma Inc shares have moved 62.95%, while the 5-day performance has seen it change 11.27%. Over the past 30 days, the shares of BridgeBio Pharma Inc (NASDAQ:BBIO) have changed 33.73%. Short interest in the company has seen 21.99 million shares shorted with days to cover at 6.62.
Wall Street analysts have a consensus price target for the stock at $72, which means that the shares’ value could jump 38.08% from the levels at last check today.. The projected low price target is $72.0 while the price target rests at a high of $72.0. In that case, then, we find that the latest price level in today’s session is -61.51% off the targeted high while a plunge would see the stock gain -61.51% from the levels at last check today..
BridgeBio Pharma Inc (BBIO) estimates and forecasts
The company’s shares have gained 70.10% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -3.04% over the past 5 years.
BBIO Dividends
BridgeBio Pharma Inc is expected to release its next earnings report on 2025-Apr-29 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
BridgeBio Pharma Inc (NASDAQ:BBIO)’s Major holders
Insiders own 4.93% of the company shares, while shares held by institutions stand at 98.14% with a share float percentage of 103.23%. Investors are also buoyed by the number of investors in a company, with BridgeBio Pharma Inc having a total of 410.0 institutions that hold shares in the company. The top two institutional holders are KOHLBERG KRAVIS ROBERTS & CO. L.P. with over 31.06 million shares worth more than $786.77 million. As of 2024-06-30, KOHLBERG KRAVIS ROBERTS & CO. L.P. held 16.5582% of shares outstanding.
The other major institutional holder is VIKING GLOBAL INVESTORS LP, with the holding of over 25.12 million shares as of 2024-06-30. The firm’s total holdings are worth over $636.31 million and represent 13.3917% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund . As of Mar 31, 2025 , the former fund manager holds about 2.56% shares in the company for having 4.85 shares of worth $215.37 million while later fund manager owns 3.79 shares of worth $168.26 million as of Mar 31, 2025 , which makes it owner of about 2.00% of company’s outstanding stock.
